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Summary
The host response to Clostridium difficile infection in antibiotic-treated
mice is characterized by robust recruitment of Gr-1+ cells, increased
expression of inflammatory cytokines including tumour necrosis factor-a
(TNF-a), and the development of severe epithelial damage. To investigate
the role of Gr-1+ cells and TNF-a during C. difficile colitis, we treated
infected mice with monoclonal antibodies against Gr-1 or TNF-a. Mice
were challenged with vegetative cells of C. difficile strain VPI 10463 fol-
lowing treatment with the third-generation cephalosporin ceftriaxone. Cef-
triaxone treatment alone was associated with significant changes in
cytokine expression within the colonic mucosa but not overt inflamma-
tory histopathological changes. In comparison, C. difficile infection follow-
ing ceftriaxone treatment was associated with increased expression of
inflammatory cytokines and chemokines including Cxcl1, Cxcl2, Il1b, Il17f
and Tnfa, as well as robust recruitment of Ly6CMid Gr-1High neutrophils
and Ly6CHigh Gr-1Mid monocytes and the development of severe colonic
histopathology. Anti-Gr-1 antibody treatment resulted in effective deple-
tion of both Ly6CMid Gr-1High neutrophils and Ly6CHigh Gr-1Mid mono-
cytes: however, we observed no protection from the development of
severe pathology or reduction in expression of the pro-inflammatory cyto-
kines Il1b, Il6, Il33 and Tnfa following anti-Gr-1 treatment. By contrast,
anti-TNF-a treatment did not affect Gr-1+ cell recruitment, but was associ-
ated with increased expression of Il6 and Il1b. Additionally, Ffar2, Ffar3,
Tslp, Tff and Ang4 expression was significantly reduced in anti-TNF-a-trea-
ted animals, in association with marked intestinal histopathology. These
studies raise the possibility that TNF-a may play a role in restraining
inflammation and protecting the epithelium during C. difficile infection.
Keywords: colitis; epithelium; microbiome; mucosal inflammation;
neutrophil
Introduction
The inflammatory signals that support leucocyte recruit-
ment, intestinal histopathology and inflammatory cyto-
kine production during Clostridium difficile infection are
still not completely understood. Recent studies have iden-
tified key roles for Myeloid Differentiation Primary
Response 88, Nucleotide Binding Oligomerization
Domain 1, and Caspase Recruitment Domain Containing
Protein in promoting neutrophil recruitment and the
production of inflammatory cytokines in response to
C. difficile infection.1–3 Additionally, signalling of Toll-like
Abbreviations: GM-CSF, Granulocyte-Macrophage Colony Stimulating Factor; TNF-a, Tumor Necrosis Factor Alpha; IL, Inter-
leukin; IFNc, Interferon Gamma; CCL, Chemokine (C-C Motif) Ligand; CXCL, Chemokine (C-X-C Motif) Ligand; CSF, Colony
Stimulating Factor; MIF, Macrophage Migration Inhibitory Factor; iNOS, Inducible Nitric Oxide Synthase (NOS2); RegIIIc,
Regenerating Islet-Derived 3 Gamma; SLPI, Secretory leukocyte peptidase inhibitor; Tgfb1, Transforming Growth Factor beta 1;
Ang4, Angiogenin 4; TCCFA, Taurocholate Cycloserine Cefoxitin Fructose Agar; TNBS, 2,4,6-trinitrobenzenesulfonic acid; BHIS,
Brain Heart Infusion Supplemented with 0.1% Cysteine; SSC, Side Scatter; FSC, Forward Scatter
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receptors 4 and 5 has been shown to prevent the develop-
ment of severe intestinal histopathology during C. difficile
infection.4,5 However, the role of tumour necrosis factor-
a (TNF-a) in promoting epithelial damage, leucocyte
recruitment and inflammatory cytokine expression during
C. difficile infection has yet to be investigated.
Antibiotic pre-treatment is required to infect conven-
tional mice with C. difficile.1–4,6–11 However, antibiotic
treatment is also capable of modulating inflammatory
responses and immune cell function.12–16 In vitro studies
have demonstrated reduced expression of inflammatory
mediators from monocytes stimulated with live fungal15
or heat-killed bacterial13 cells following moxifloxacin and
co-trimoxazole treatment, respectively. Macrolide antibiot-
ics can also affect inflammatory functions of pulmonary
epithelial cells and modulate TNF-a, interleukin-8 (IL-8)
and Granulocyte-macrophage colony stimulating factor
production by these cells.16–19 Ceftriaxone is a third-gener-
ation cephalosporin with bactericidal activity against both
Gram-positive and Gram-negative bacteria.20–22 Cefoperaz-
one, another third-generation cephalosporin, can markedly
alter the composition of the intestinal microbiota and ren-
der mice susceptible to C. difficile infection.8,10 In the cur-
rent study, we investigated the ability of ceftriaxone to
permit C. difficile infection, and whether ceftriaxone treat-
ment alone was sufficient to induce colonic inflammation.
Tumour necrosis factor-a promotes leucocyte recruit-
ment and the expression of inflammatory cytokines dur-
ing mucosal inflammation.23–25 TNF-a expression is
significantly increased during acute C. difficile colitis,9
and macrophage TNF-a production is also enhanced by
exposure to C. difficile toxins.26 Gr-1 is an epitope found
on both Ly6C and Ly6G, and is expressed on neutrophils,
inflammatory monocytes, and plasmacytoid dendritic
cells.9,27–29 Gr-1+ cells are recruited in large numbers to the
large intestine in response to C. difficile infection,1–3,9 and
protect against bacterial dissemination and mortality.2,3
However, much remains unknown about the contributions
of Gr-1+ cells and TNF-a in promoting intestinal histopa-
thology, leucocyte recruitment, and the expression of
inflammatory cytokines during C. difficile colitis.
Materials and methods
Bacterial culture and growth conditions
Clostridium difficile was prepared for infection as
described previously.8,10 Briefly, an overnight culture of
C. difficile strain VPI 10463 (ATCC 43255) was back-
diluted 1 : 10 in fresh brain–heart infusion broth supple-
mented with 0.1% cysteine and grown for 4–6 hr. The
culture was then collected, washed three times in deoxy-
genated PBS, and diluted to the desired dose. Mice were
challenged via oral gavage. The inoculum was serially
diluted and plated on brain–heart infusion supplemented
with 0.1% cysteine to confirm dosage. Clostridium difficile
was grown and prepared for gavage in a Coy anaerobic
chamber (Coy Laboratory Products, Grass Lake, MI).
Animals and housing
C57BL/6 male mice aged 5–9 weeks at the time of antibi-
otic pre-treatment were used in the current study. All
experiments were conducted under a protocol approved
by the University Committee on Use and Care of Animals
at the University of Michigan. All mice were purchased
directly from Jackson Laboratories (Bar Harbor, ME) or
obtained from an in-house colony founded by Jackson
breeders. Mice were housed with autoclaved bedding,
food and water. All animal manipulations were carried
out in a laminar flow hood.
Antibiotic treatment and infection
For ceftriaxone and C. difficile infection studies, mice
were treated with ceftriaxone (05 g/l) (Sigma, St Louis,
MO) given ad libitum in their drinking water for 4 days.
Antibiotic water was replaced every other day. Mice were
then given a 2-day recovery period on drinking water
without antibiotic before infection with C. difficile as
described previously.8,10 Ceftriaxone-treated mice were
given the antibiotic regimen only, and untreated animals
were not manipulated at all.
For C. difficile infection studies, mice received
506  031 Log10 colony-forming units vegetative C. dif-
ficile via oral gavage on day 2 (Fig. 1). Clostridium diffi-
cile-infected animals were monitored for signs of severe
disease (hunched posture, lethargy, weight loss exceeding
20% of baseline body weight) and were humanely killed
if moribund. All surviving animals were killed on day 4
for subsequent analysis (Fig. 1).
Antibody administration
Mice were given intraperitoneal injections of 250 lg of
anti-TNF-a monoclonal antibody (mAb; clone MP6-XT3)
1 day before infection with C. difficile or injections of
250 lg of anti-Gr-1 mAb (clone RB6-8C5) 1 day before
and 1 day after infection. Mouse serum (Sigma) injec-
tions were administered to control mice.
Histology
Colonic tissue was collected from the midpoint of the
colon and either flash-frozen in liquid nitrogen for
subsequent DNA extraction or stored in RNAlater (Life
Technologies, Grand Island, NY) for RNA analysis. Whole
colons were excised from representative mice and
prepared for histological analysis as described previ-
ously.8,10 Cassettes were processed, paraffin embedded,
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Figure 1. (a) Experimental approach and timeline. (b–e) Effect of ceftriaxone treatment and Clostridium difficile infection on the colonic micro-
biota (day 4). (b) Diversity (Inverse Simpson Index) of the mucosa-associated bacterial communities of untreated, ceftriaxone-treated, or ceftriax-
one-treated and C. difficile infected mice. (c–e) Relative abundance of the mucosa-associated bacterial communities of the mice in panel b. The
operational taxonomic units (OTUs) were ordered by decreasing abundance of genera in the untreated group. Data are shown as mean  SEM
relative abundance. The Family and Genus-level taxonomies are displayed along the x-axis and the Phylum-level taxonomy is identified in the
shading of individual bars.
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sectioned and used to prepare haematoxylin & eosin
stained slides (McClinchey Histology Lab Inc., Stock-
bridge, MI).
Representative images were acquired on an Olympus
BX40 light microscope (Olympus Corporation, Center
Valley, PA) using a QIMAGING MICROPUBLISHER RTV 50 5
megapixel camera (QImaging Corporation, Surrey, BC,
Canada) at a total magnification of 9 400. Images were
acquired using QCAPTURE SUITE PLUS (QImaging Corpo-
ration) version 3.1.3.10. Image and panel assembly were
performed in ADOBE PHOTOSHOP CS5, version 12.0 (Adobe,
San Jose CA). Image processing was restricted to global
adjustments of brightness, contrast and image size.
Histopathological examination
Histological sections were coded, randomized and scored
in a blinded manner. The slides were first scored categori-
cally on a 0–5 scale for epithelium damage and for inflam-
mation, using defined criteria. Epithelium damage was
scored as follows: 0, intact epithelium; 1, minimal, scat-
tered goblet cell loss with no significant epithelium destruc-
tion and no histologically defined loss of surface integrity;
2, widespread moderate goblet cell loss with no significant
epithelium destruction and no histologically defined loss of
surface integrity; 3, moderate to extensive widespread gob-
let cell loss with scattered epithelium destruction and histo-
logically defined loss of surface integrity; 4, extensive
epithelium and goblet cell destruction with histologically
defined loss of surface integrity; 5, severe epithelium
destruction and goblet cell destruction with widespread
histologically apparent loss of surface integrity. Inflamma-
tion was scored as follows: 0, no inflammation; 1, minimal
multifocal leucocytic infiltrates; 2, moderate multifocal
leucocytic infiltrates and low level oedema (greater submu-
cosal involvement); 3, significant multifocal leucocytic
infiltrates, oedema, submucosal involvement; 4, extensive
multifocal leucocytic infiltrates, oedema, extensive submu-
cosal involvement; 5, severe multifocal leucocytic infil-
trates, extensive oedema and submucosal involvement with
luminal involvement and/or abscess formation. The slides
were then assigned an overall score using a rank-order
scoring system. The total of both categorical scores (epithe-
lium damage and inflammation) were used to rank all the
slides in the study in order of increasing severity of histo-
pathological changes (1 = least, 16 = most). This method
offers significant advantages over straight categorical scor-
ing systems for comparing histological changes between
groups and has been previously reported for scoring C. dif-
ficile-induced intestinal pathology.10,30,31
RNA isolation and expression analysis
RNA was isolated and purified from colonic tissue as
described previously.9 RNA quality was assessed using an
Agilent bioanalyzer (Agilent Technologies, Santa Clara,
CA), and the concentration of RNA was assessed using a
Nanodrop instrument (Thermo Fisher Scientific, Wal-
tham, MA). Complementary DNA was generated using
the RT2 First Strand kit (Qiagen, Valencia, CA), and gene
expression was then determined using RT2 PCR cards
(Qiagen). To account for any variation between RT2 PCR
cards, cross-card normalization was performed as
described previously.9,32 The mean Ct values of two inter-
nal control genes was subtracted from the Ct of the gene
in question to generate DCt (dCt) values.33 The 2ddCt
method was used to calculate fold change gene expression
for all comparisons.34 All reactions were run on a Light-
Cycler 480 (Roche, Indianapolis, IN).
DNA isolation, amplicon library preparation, 454 py-
rosequencing and microbiome community analysis
All procedures and analyses were performed as previously
described.9 Briefly, DNA was isolated from rinsed colonic
tissue and V3-V5 16S ribosomal RNA gene amplicon
libraries were generated. They were then sequenced on a
Roche 454 GS Junior Titanium platform according to the
manufacturer’s specifications. Bacterial 16S rRNA gene
sequences were processed using the microbial ecology
software suite MOTHUR35 to generate operational taxo-
nomic units (OTUs) at a 3% level of difference (approxi-
mating species-level differences). These data were then
imported into the software package R and analysed using
the R add on-package VEGAN.36 Rank abundance plots
were generated by selecting for the OTUs that contributed
to > 05% of the population. The content of each treated
tissue was ordered according to the average rank order of
its untreated counterpart. Taxonomic classification of an
OTU was assigned within MOTHUR by identifying the con-
sensus sequence of the OTU and assigning taxonomy
using a Bayesian classifier trained on an Ribosomal Data-
base Project training set (classify.otu).
Quantification of C. difficile colonization
Mucosal C. difficile colonization was determined using a
species-specific quantitative PCR of DNA isolated from
colonic tissue. The C. difficile-specific qPCR was per-
formed as described previously.8,37 All reactions were car-
ried out in a total volume of 10 ll. Each reaction
contained 2 ll of template primers, 625 pmol forward
and reverse tcdB primers, and 1 pmol tcdB probe. The
cycling conditions and probe and primer sequences are
identical to those used previously.8 Raw Ct values were
normalized to signal from a single-copy host internal
control gene to generate dCt values.8,34 The dCt values
were then converted to ‘C. difficile genomes/g tissue’
using a standard curve generated with known amounts of
vegetative C. difficile and colonic tissue.
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Colonic leucocyte isolation
Colonic leucocytes were isolated as described previ-
ously2,9,38 with modification. Colonic tissue was minced
with serrated scissors and incubated in 20 ml of Hanks’
balanced salt solution supplemented with 25% fetal
bovine serum, 5 mM EDTA and 1 mM dithiothreitol for
20 min at 37°. After washing, tissue was incubated in
20 ml Hanks’ balanced salt solution supplemented with
25% fetal bovine serum, 400 U/ml collagenase type 3
(Worthington Biochemical, Freehold NJ), and 05 mg/ml
DNase I (Roche) for 60 min at 37°. Samples were then
resuspended in 20% Percoll (Sigma) in PBS, and centri-
fuged at 900 g for 30 min at room temperature. The
resulting single-cell suspensions were stained for analysis
of cell surface marker expression via flow cytometry.
Flow cytometry and staining
Flow cytometric staining was performed as described pre-
viously.9 Briefly, cells were blocked with unlabelled
FcRIII/II, and subsequently stained with fluorescently
labelled antibodies for 30 min. Cells were then washed
and finally suspended in stabilizing fixative (BD Bio-
sciences, San Jose, CA). All data were collected on a
three-laser Canto II using FACSDIVA software (BD Bio-
sciences). All subsequent analysis was performed using
FLOWJO (Treestar, Ashland, OR). The following antibodies
were used for flow cytometric analysis of intestinal leuco-
cytes. CD11c (clone HL3), CD45 (clone 30-F11), CD11b
(clone M1/70), Gr-1 (clone RB6-8C5), and Ly6C (clone
AL-21) as well as FcRIII/II (clone 24G2). All antibodies
were purchased from BD Biosciences and Biolegend (San
Diego, CA).
Statistical analysis
Unpaired two-tailed t-tests were used to identify statisti-
cally significant differences in gene expression between
untreated and ceftriaxone-treated mice. For all other
analyses, statistically significant changes were identified
using a one-way analysis of variance with Tukey’s post
hoc test for multiple comparisons. For all quantitative
PCR data (colonic gene expression and C. difficile coloni-
zation), statistical analysis was performed on normalized
dCt values. Significance was set at P ≤ 005 in all analy-
ses.
Results
Effect of ceftriaxone treatment on the colonic
microbiota
To assess the effect of ceftriaxone treatment on the diver-
sity and membership of the colonic microbiota, animals
were given ceftriaxone (05 g/l) in their drinking water
for 4 days and analysed 4 days later (Fig. 1a). 454-pyrose-
quencing analysis of 16S amplicon libraries generated
from colonic tissue from untreated and ceftriaxone-trea-
ted mice allowed for characterization and comparisons of
the colonic mucosa-associated microbiota between
groups.39 This analysis revealed that 4 days of ceftriaxone
treatment was sufficient to significantly decrease the
diversity of the mucosa-associated microbiota, compared
with untreated mice, at 4 days post-antibiotic (Fig. 1b).
While untreated animals possessed a complex microbiota
comprised primarily of members of the phyla Bacteroide-
tes and Firmicutes (Fig. 1c), ceftriaxone treatment was
associated with a marked shift in the membership of the
community towards a composition dominated by a single
Firmicute; Enterococcaceae (Fig. 1d). These experiments
demonstrated that ceftriaxone treatment was sufficient to
significantly decrease the diversity and markedly alter the
membership of the colonic microbiota even 4 days after
the cessation of antibiotic treatment.
Effect of ceftriaxone treatment on colonic gene
expression
To investigate the effect of ceftriaxone treatment and the
associated loss of microbial diversity on immune regula-
tion the colonic mucosa, quantitative RT-PCR was used
to examine colonic cytokine expression following ceftriax-
one treatment. Ceftriaxone treatment was associated with
significantly increased expression of the chemokines Ccl5
and Cxcl9, and significantly decreased expression of
Ccl11, Ccl3 and Cxcl2 (Fig. 2a,b). Additionally, Il2, Il10,
Il5 and Il3 expression was all significantly increased fol-
lowing ceftriaxone treatment, while expression of Il23a,
Il17f, Il1b, Il17a, Tgfb and Slpi was decreased (Fig. 2c–e).
Examination of histopathological sections from the colons
of ceftriaxone-treated mice revealed no evidence of cellu-
lar infiltration or inflammation in these animals (see Sup-
porting information, Figure S1). Taken together, these
data demonstrate that ceftriaxone treatment alone induces
significant changes in the cytokine expression pattern in
the colonic mucosa but does not result in overt inflam-
matory histopathological changes.
Clostridium difficile infection following ceftriaxone
treatment
To determine if ceftriaxone treatment was sufficient to
permit colonization and infection by C. difficile, ceftriax-
one-treated mice were challenged with vegetative cells
(105 colony-forming units) from C. difficile strain VPI
10463 2 days after the cessation of ceftriaxone treatment
and were followed for an additional 2 days (Fig. 1a). Sig-
nificant colonization by C. difficile was detected in the
colonic mucosa of infected mice via quantitative PCR by
ª 2014 John Wiley & Sons Ltd, Immunology, 144, 704–716708
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2 days post challenge (Fig. 3a). Colonization did not
cause a shift in the membership (Fig. 1c–e) or diversity
(Fig. 1b) of the colonic microbiota beyond that attribut-
able to ceftriaxone treatment alone. Clostridium difficile
colonization of ceftriaxone-treated mice resulted in an
influx of inflammatory cells into the colon and marked
epithelial damage, indicative of active infection (Fig. 4).
Taken together, these data demonstrate that ceftriaxone
treatment renders mice susceptible to C. difficile coloniza-
tion with the concomitant development of colitis.
Host responses to C. difficile colitis
In order to characterize the mucosal response to C. diffi-
cile colitis following ceftriaxone treatment, colonic gene
expression was examined. Infection with C. difficile was
associated with increased expression of Inos, Slpi, Il1b, Il6,
Il17f, Ifng, Il17a, Il22, Il2, Il33 and Tnfa (Fig. 7 and 8c).
Expression of Il18, Il23, Il12, Il3, Il4, Il5, Il13, Il10, Tgfb
and Ang4 was not induced in response to C. difficile
infection (Fig. 7 and 8c). Consistent with the robust cel-
lular recruitment observed in histological sections from
C. difficile-infected mice (Fig. 4), there was increased
expression of the CC chemokines Ccl2, Ccl3, Ccl4, Ccl5
and Ccl7, but not Ccl11 or Ccl24 (Fig. 6a,b) and the
expression of the CXC chemokines Cxcl1 and Cxcl2, as
well as the neutrophil stabilization factors Csf2 and Csf3
were also increased (Fig. 6c,d). Hence, these data indicate
that the mucosal response to C. difficile infection is char-
acterized by increased expression of CC and CXC chemo-
kines and inflammatory cytokines including Il1b, Il6, Il17f
and Tnfa.
Flow cytometry was used to further delineate the leuco-
cyte populations recruited to the colon following C. difficile
infection. Analysis of the side scatter (SSC) and forward
scatter (FSC) parameters of CD45+ leucocytes revealed a
drastic influx of FSCMid SSCHigh leucocytes in response to
C. difficile infection (Fig. 5a). Nearly all of the recruited
FSCMid SSCHigh cells were CD11bHigh CD11cLow inflam-
matory myeloid cells (Fig. 5b). Within the
CD11bHigh CD11cLow population, there were two popula-
tions, the largest of which were Ly6CMid Gr-1High neu-
trophils, and a smaller population of Ly6CHigh Gr-1Mid
monocytes (Fig. 5c). Hence, these data demonstrate
marked recruitment of two distinct Gr-1+ leucocyte pop-
ulations, Ly6CMid Gr-1High neutrophils and Ly6CHigh
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Figure 2. (a–e) Effect of ceftriaxone treatment
on colonic inflammatory gene expression (day
4). Mice were treated as outlined in Figure 1.
Host gene expression was measured by quanti-
tative PCR as described in the methods; n ≥ 9
per group. Data are shown as mean  SEM
fold change gene expression of ceftriaxone-
treated animals compared with untreated mice.
*P < 005 as compared with untreated ani-
mals.
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Gr-1Mid monocytes, to the colon in response to C. difficile
colitis.
The role of Gr-1+cells during C. difficile colitis
To determine the role of Gr-1+ cells in supporting the
mucosal inflammatory response to C. difficile infection,
animals were treated with an anti-Gr-1 mAb (clone RB6-
8C5) 1 day before and 1 day after C. difficile infection
(Fig. 1a). There was a marked reduction in the frequency
of CD11bHigh CD11cLow inflammatory myeloid cells, as
well as a reduction in both the Ly6CMid Gr-1High neutro-
phil and Ly6CHigh Gr-1Mid monocyte populations follow-
ing anti-Gr-1 treatment (Fig. 5b,c). However, anti-Gr-1
treatment had no effect on C. difficile levels in the colonic
mucosa (Fig. 3a).
Compared with C. difficile infection alone, Il5, Il12 and
Il22 expression was significantly reduced, and Il3 expres-
sion was significantly increased, in C. difficile-infected
anti-Gr-1-treated mice (Fig. 7c–e). However, expression
of Il1b, Il6, Csf2, Csf3, Tnfa and Il33 was unchanged fol-
lowing anti-Gr-1 treatment (Fig. 6 and 7). Expression of
Cxcl1, Cxcl2, Ccl2 and Ccl3 was also not significantly
affected by anti-Gr-1 treatment (Fig. 6a,c). Anti-Gr-1
treatment did not protect against the colonic histopathol-
ogy that developed during the normal course of infection
(Fig. 3b and 4). Taken together, these data indicate that
the expression of CC and CXC chemokines, the expres-
sion of inflammatory cytokines including Tnfa, Il1b and
Il6, and the development of severe colonic histopathology
during C. difficile colitis are all independent of the pres-
ence of Gr-1+ cells within the colon.
The role of TNF-a during C. difficile colitis
To examine the role of TNF-a in promoting inflamma-
tory myeloid cell recruitment and epithelial damage in
response to C. difficile infection, mice were treated with a
TNF-a neutralizing mAb (clone MP6-XT3) 1 day before
infection (Fig. 1a). Clostridium difficile colonization
within the colonic mucosa was equivalent between anti-
TNF-a-treated and C. difficile-infected animals (Fig. 3a).
There was near identical recruitment of
CD11bHigh CD11cLow inflammatory myeloid cells follow-
ing anti-TNF-a treatment compared with that seen in
response to C. difficile infection alone (Fig. 5b).
Ly6CMid Gr-1High neutrophil and Ly6CHigh Gr-1Mid
monocyte frequencies were also unchanged following
anti-TNF-a treatment (Fig. 5c). Consistent with this
observation, Cxcl1, Cxcl2, Ccl2 and Ccl3 expression was
not reduced in these mice (Fig. 6a,c). While the expres-
sion of Il33, Ifng and Il17f was not significantly reduced
by anti-TNF-a treatment, expression of Mif, Il1b and Il6
was all significantly increased following anti-TNF-a treat-
ment (Fig. 6d and 7). Furthermore, expression of Ccl5,
Il5 and Il22 was all significantly lower in anti-TNF-a-trea-
ted mice (Fig. 6b and 7d,e).
Epithelial damage was prominent in anti-TNF-a-treated
mice (Fig. 4) and anti-TNF-a treatment was associated
with more severe colonic histopathology (Fig. 3b). Anti-
TNF-a treatment was also associated with a significant
decrease in the expression levels of the colonic goblet cell
gene Ang4, the free fatty acid receptors Ffar2 and Ffar3,
epithelium-derived effector and signal molecules encoded
by Tslp, Tff, Defb3 and Lyz1, in addition to a trend
toward higher expression levels of Slpi compared with
C. difficile infection alone (Fig. 8). Additionally, there was
a trend towards decreased expression of the goblet cell-
specific gene Muc2 after anti-TNF-a treatment (Fig. 8a).
Taken together, these data indicate that anti-TNF-a treat-
ment was associated with enhanced colonic epithelial dys-
function/destruction and can augment the epithelial
inflammatory milieu during C. difficile infection.
Discussion
Together, these data demonstrate that ceftriaxone-treated
mice are a robust model for investigating the innate acute
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Figure 3. (a) Mucosal Clostridium difficile colonization as deter-
mined by species-specific quantitative PCR (Day 4). n ≥ 9 mice per
group. Data are shown as mean  SEM. CDI = C. difficile infected.
LOD = Limit of Detection. *P < 005 as compared with untreated
animals. Mice were treated as outlined in Fig. 1 and the methods.
(b) Rank order analysis of colonic histopathological sections from
Untreated, C. difficile-infected, C. difficile-infected and anti-Gr-1-
treated, C. difficile infected and anti-tumour necrosis factor-a
(TNFa) treated animals (day 4). Slides were ordered on the basis of
disease severity, with 16 having the most severe histopathology.
n = 4 mice per group.
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inflammatory response to C. difficile infection. In addi-
tion to altering the composition of the colonic microbi-
ome, ceftriaxone treatment alone was also capable of
modulating colonic cytokine and chemokine expression
4 days after the cessation of antibiotic treatment. While
ceftriaxone treatment was associated with significantly
altered expression of several genes induced during C. dif-
ficile colitis, the induction of the inflammatory cytokines
and chemokines associated with C. difficile infection was
significantly greater than that seen with ceftriaxone treat-
ment alone (see Supporting information, Figure S2).
Additionally, ceftriaxone treatment alone did not produce
any histopathological changes in the colonic mucosa
(see Supporting information, Figure S1). Hence, while
ceftriaxone treatment is capable of modulating colonic
gene expression, we propose it is not a confounding fac-
tor in evaluating the host inflammatory response in this
model of infectious colitis.
Anti-TNF-a treatment was associated with an aug-
mented epithelial inflammatory response to C. difficile
infection. Previous studies have reported a role for TNF-a
signalling in promoting myeloid cell recruitment during
mucosal inflammation.23,24 TNF-a can enhance the
expression of CCL3 during chemically induced pulmo-
nary inflammation,24 and interference with TNF-a signal-
ling reduces neutrophil recruitment in response to acute
allergic airway inflammation.23 TNF-a can contribute to
inflammatory cytokine expression and tissue damage
CDIUntreated
CDI + Anti-Gr-1 CDI + Anti-TNF-α
Figure 4. Photomicrographs of representative
haematoxylin & eosin (H&E) -stained colonic
sections from Untreated, Clostridium difficile-
infected, C. difficile-infected and anti-Gr-1-
treated, C. difficile-infected and anti- tumour
necrosis factor-a (TNF-a)-treated animals (day
4). Cross-sections of colonic crypts (upper
images) and longitudinal sections of the epi-
thelial–luminal interface (lower images) are
shown for each treatment. Black arrowheads
indicate infiltrating inflammatory cells, while
grey arrowheads indicate areas of epithelial
damage. All animals were treated as outlined
in Fig. 1. Total magnification for all images is
400 9. CDI = C. difficile infected.
ª 2014 John Wiley & Sons Ltd, Immunology, 144, 704–716 711
Gr-1+ Cells and TNF during C. difficile Colitis
during mucosal inflammation.25,40 Directly applicable to
gastrointestinal inflammation, during 2,4,6-trinitroben-
zenesulphonic acid colitis, TNF-a signalling promotes
both IL-18 and TNF-a expression as well as the develop-
ment of intestinal histopathology.25 Anti-TNF-a treat-
ment had no effect on Cxcl1, Cxcl2, Ccl2 and Ccl3
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Figure 5. Flow cytometric analysis of colonic
leucocytes from Untreated, Clostridium diffi-
cile-infected, C. difficile-infected and anti-Gr-1-
treated, C. difficile infected and anti-tumour
necrosis factor (TNF-a ) -treated animals (day
4). (a) Analysis of forward-scatter (FSC) and
side-scatter (SSC) properties of total colonic
CD45+ leucocytes. (b) Analysis of CD11b and
CD11c expression profiles of SSCHigh FSCLow
CD45+ leucocytes as defined in panel (a). (c)
Analysis of Ly6C and Gr-1 expression profiles
of the CD11bHigh CD11cLow population
defined in panel (b). CDI = C. difficile
infected. The number in bold type indicates
the percentage of total CD45+ leucocytes con-
tained within the indicated gate.
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Figure 6. (a–d) Effect of anti-Gr-1 and anti-
tumour necrosis factor-a (TNF-a) treatment
on colonic inflammatory chemokine expression
during C. difficile colitis (day 4). Colonic gene
expression was measured via quantitative PCR
as outlined in the Materials and methods.
n ≥ 8 per group. Data are shown as
mean  SEM fold change gene expression of
C. difficile infected (black bars), C. difficile-
infected and anti-Gr-1-treated (white bars),
and C. difficile infected and anti-TNFa treated
(gray bars) animals as compared with
untreated mice. *P < 005 compared with
untreated animals. Brackets indicate P < 005
for the differences between the indicated
groups.
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expression during C. difficile colitis, and we observed no
reduction in neutrophil and monocyte recruitment under
these conditions. However, colonic expression of Il1b and
Il6 was increased following anti-TNF-a treatment. Hence,
despite its relatively low level of expression, TNF-a is
involved in the inflammatory response during C. difficile
colitis but the induction of CC and CXC chemokines and
subsequent myeloid cell recruitment during infection are
largely TNF-a-independent.
While TNF-a is generally held to be a pro-inflamma-
tory mediator that can participate in indirect epithelial
damage, there is precedent for an epithelium cytoprotec-
tive role for this cytokine, as our data suggest may occur
in this infection model.41–43 TNF-a signalling can protect
against severe intestinal histopathology during Citrobacter
rodentium infection.41 Furthermore, cellular infiltration
and intestinal epithelial damage during DSS colitis are
enhanced in the absence of TNF-a.42,43 Following anti-
TNF-a treatment we observed decreased expression of the
free fatty acid receptors Ffar2 and Ffar3, as well as Defb3,
Lyz1 and Tslp, consistent with the severe colonic epithelial
damage present in these animals. Anti-TNF-a treatment
was also associated with significantly decreased expression
of Ang4 and a trend towards decreased expression of
Muc2, two genes whose expression is specific to goblet
cells within the gastrointestinal tract,44–46 suggesting
reduced goblet cell function. Additionally, colonic histo-
pathology was most severe following anti-TNF-a treat-
ment. Hence, our data are consistent with these other
models of colitis where TNF-a plays a role in protecting
the colonic epithelium from damage during inflamma-
tion, and suggests an epithelial-protective role for TNF-a
during acute, severe C. difficile infection.
One model that could explain the association between
anti-TNF-a treatment and increased inflammatory
responses and epithelial damage is that TNF-a signalling
may restrain host inflammatory responses by promoting
the clearance of translocated commensal bacteria. Previ-
ous studies have demonstrated the dissemination of com-
mensal bacterial to distal sites during C. difficile
infection,1,2 and have also suggested a role for these trans-
located bacteria in promoting innate inflammatory
responses, including the production of IL-1b.1 TNF-a sig-
nalling can activate macrophages and enhance their bacte-
ricidal capacity,47 and mucosal macrophages represent a
large resident population within the colonic lamina pro-
pria with the capacity to eliminate invading bacteria.48
Hence, in the absence of TNF-a signalling, translocated
commensal bacteria may be less efficiently cleared by
macrophages within the colonic lamina propria, leading
to increased activation of inflammatory pathways and
enhanced colonic tissue damage.
Despite the robust recruitment of Ly6CMid Gr-1High
neutrophils and Ly6CHigh Gr-1Mid monocytes in response
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Figure 7. (a–g) Effect of anti-Gr-1 and anti-
tumour necrosis factor-a (TNF-a ) treatment
on colonic inflammatory cytokine expression
during C. difficile colitis. Host gene expression
was measured via quantitative PCR as
described in the methods; n ≥ 7 per group.
Data are shown as mean  SEM fold change
gene expression of C. difficile infected (black
bars), C. difficile infected and anti-Gr-1 treated
(white bars), and C. difficile infected and anti-
TNF-a treated (grey bars) animals as compared
with untreated mice. CDI = C. difficile infected
*P < 005 compared with untreated animals.
Brackets indicate P < 005 for the differences
between the indicated groups.
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to C. difficile infection, we observed no reduction in colo-
nic expression of CC and CXC chemokines or proinflam-
matory cytokines including Il1b, Il6, Il33 and Tnfa
following anti-Gr-1 treatment. Neutrophil recruitment is
commonly associated with the development of inflamma-
tion at mucosal sites23,49,50 and neutrophils are a well-
documented source of inflammatory cytokines, including
IL-6, as well as the neutrophil chemokine IL-8.51–53 While
several studies have investigated the role of neutrophils in
reducing host mortality and preventing the translocation
of bacteria during C. difficile infection,2,3 to our
knowledge the role of neutrophils as a cellular source of
chemokine and cytokine expression has not been exten-
sively investigated. Despite effective depletion of both
neutrophils and monocytes following our anti-Gr-1 treat-
ment, colonic CC and CXC chemokine expression as well
as Il1b, Il6, Il33 and Tnfa expression was unchanged.
Consistent with the significant reduction in Il22 expres-
sion, a cytokine with a vital role in promoting wound
healing and preventing epithelial damage at mucosal
sites,54–56 we observed no protection from intestinal epi-
thelial damage in anti-Gr-1-treated mice. Taken together,
our data strongly suggest that the recruited Gr-1+ popula-
tions, including neutrophils, are not responsible for the
robust inflammatory cytokine expression or epithelial
damage observed during C. difficile infection.
One potential explanation for our observation that
depletion of Gr-1+ cell populations had minimal effect on
colonic cytokine and chemokine expression is that Gr-1+
cells, including neutrophils, are not a major cellular
source of these inflammatory mediators during the host
response to C. difficile colitis. A recent study has reported
decreased intestinal IL-1b and CXCL1 production follow-
ing neutrophil depletion.1 However, that study used a less
severe model of disease with 100% survival of infected
animals at 5 days-post infection,1 while the model used
in the current study, similar to other models based on
the third-generation cephalosporin cefoperazone,8,10
resulted in high morbidity by 2 days post infection.
Hence, in the context of such an overwhelming infection,
alternative pathways and sources of inflammatory cyto-
kine expression may respond and effectively supersede the
cytokine production by neutrophils observed in less
severe models. Additionally, Hasegawa et al.1 used a com-
bination of seven antibiotics to permit C. difficile infec-
tion, compared with the single antibiotic, ceftriaxone,
used in the current study. These two antibiotic treatments
will likely result in different colonic microbial communi-
ties, whose members may differentially stimulate host cell
subsets and result in the activation of distinct inflamma-
tory pathways in response to the same challenge.
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Figure S1. Photomicrographs of representative Hema-
toxylin and Eosin (H&E) stained colonic sections from
both uninfected (untreated) and ceftriaxone treated mice
(day 4).
Figure S2. (a–e) Comparison of ceftriaxone treatment
alone and Clostridium difficile infection following ceftriax-
one treatment on colonic inflammatory gene expression
(day 4).
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